{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:58:37Z","timestamp":1792792717370,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,18]]},"DOI":"10.7759\/cureus.88236","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T14:43:30Z","timestamp":1752849810000},"source":"Crossref","is-referenced-by-count":4,"title":["Safety and Efficacy of Dupilumab, Omalizumab, and Mepolizumab in Moderate-to-Severe Asthma: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Zainab T","family":"O. Omar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moravia","family":"Owodeha-Ashaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okelue E","family":"Okobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Egyin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiugo","family":"Okoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian O","family":"Odion-Omonhimin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kingsley O","family":"Ozojide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebere M","family":"Nwachukwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40629-022-00220-x","article-title":"Indicating biologics for chronic rhinosinusitis with nasal polyps (CRSwNP): recommendations by German allergy and ORL societies AeDA and DGHNO for dupilumab, omalizumab, and mepolizumab","volume":"31","author":"Klimek L","year":"2022","unstructured":"Klimek L, F\u00f6rster-Ruhrmann U, Beule AG, et al.. Indicating biologics for chronic rhinosinusitis with nasal polyps (CRSwNP): recommendations by German allergy and ORL societies AeDA and DGHNO for dupilumab, omalizumab, and mepolizumab. Allergo J Int. 2022, 31:149-60. 10.1007\/s40629-022-00220-x","journal-title":"Allergo J Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/all.14510","article-title":"Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines","volume":"76","author":"Agache I","year":"2021","unstructured":"Agache I, Song Y, Posso M, et al.. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines. Allergy. 2021, 76:45-58. 10.1111\/all.14510","journal-title":"Allergy"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000519228","article-title":"Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis","volume":"183","author":"Wu Q","year":"2022","unstructured":"Wu Q, Zhang Y, Kong W, et al.. Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis. Int Arch Allergy Immunol. 2022, 183:279-88. 10.1159\/000519228","journal-title":"Int Arch Allergy Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23234","article-title":"Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: a systematic review of the current knowledge towards an attempt to compare agents' efficacy","volume":"14","author":"Papacharalampous GX","year":"2024","unstructured":"Papacharalampous GX, Constantinidis J, Fotiadis G, Zhang N, Bachert C, Katotomichelakis M. Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: a systematic review of the current knowledge towards an attempt to compare agents' efficacy. Int Forum Allergy Rhinol. 2024, 14:96-109. 10.1002\/alr.23234","journal-title":"Int Forum Allergy Rhinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603312","article-title":"Molecular targets for biological therapies of severe asthma","volume":"11","author":"Pelaia C","year":"2020","unstructured":"Pelaia C, Crimi C, Vatrella A, Tinello C, Terracciano R, Pelaia G. Molecular targets for biological therapies of severe asthma. Front Immunol. 2020, 11:603312. 10.3389\/fimmu.2020.603312","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12038","article-title":"Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab","volume":"11","author":"Li L","year":"2021","unstructured":"Li L, Wang Z, Cui L, Xu Y, Guan K, Zhao B. Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab. Clin Transl Allergy. 2021, 11:e12038. 10.1002\/clt2.12038","journal-title":"Clin Transl Allergy"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.05.024","article-title":"Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a\u00a0Bayesian network meta-analysis","volume":"150","author":"Akenroye A","year":"2022","unstructured":"Akenroye A, Lassiter G, Jackson JW, Keet C, Segal J, Alexander GC, Hong H. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a\u00a0Bayesian network meta-analysis. J Allergy Clin Immunol. 2022, 150:1097-1105.e12. 10.1016\/j.jaci.2022.05.024","journal-title":"J Allergy Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2021.11.009","article-title":"Risk for postmarket black box warnings in FDA-approved monoclonal antibodies","volume":"6","author":"Hagan JB","year":"2022","unstructured":"Hagan JB, Ender E, Divekar RD, Pongdee T, Rank MA. Risk for postmarket black box warnings in FDA-approved monoclonal antibodies. Mayo Clin Proc Innov Qual Outcomes. 2022, 6:69-76. 10.1016\/j.mayocpiqo.2021.11.009","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.08.033","article-title":"Boxed warnings and off-label use of allergy medications: risks, benefits, and shared decision making","volume":"10","author":"Greiwe J","year":"2022","unstructured":"Greiwe J, Honsinger R, Hvisdas C, Chu DK, Lang DM, Nicklas R, Apter AJ. Boxed warnings and off-label use of allergy medications: risks, benefits, and shared decision making. J Allergy Clin Immunol Pract. 2022, 10:3057-63. 10.1016\/j.jaip.2022.08.033","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.01.020","article-title":"Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: a\u00a0target trial emulation","volume":"151","author":"Akenroye AT","year":"2023","unstructured":"Akenroye AT, Segal JB, Zhou G, et al.. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: a\u00a0target trial emulation. J Allergy Clin Immunol. 2023, 151:1269-76. 10.1016\/j.jaci.2023.01.020","journal-title":"J Allergy Clin Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache I","year":"2020","unstructured":"Agache I, Beltran J, Akdis C, et al.. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020, 75:1023-42. 10.1111\/all.14221","journal-title":"Allergy"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2023.2282668","article-title":"Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia","volume":"24","author":"Ali A","year":"2024","unstructured":"Ali A, Garc\u00eda E, Torres-Duque CA, et al.. Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia. Expert Rev Pharmacoecon Outcomes Res. 2024, 24:361-74. 10.1080\/14737167.2023.2282668","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13144192","article-title":"Real-world safety profile of biologic drugs for severe uncontrolled asthma: a descriptive analysis from the Spanish Pharmacovigilance Database","volume":"13","author":"Boada-Fern\u00e1ndez-Del-Campo C","year":"2024","unstructured":"Boada-Fern\u00e1ndez-Del-Campo C, Garc\u00eda-S\u00e1nchez-Colomer M, Fern\u00e1ndez-Quintana E, Poza-Guedes P, Rolingson-Landaeta JL, S\u00e1nchez-Mach\u00edn I, Gonz\u00e1lez-P\u00e9rez R. Real-world safety profile of biologic drugs for severe uncontrolled asthma: a descriptive analysis from the Spanish Pharmacovigilance Database. J Clin Med. 2024, 13:4192. 10.3390\/jcm13144192","journal-title":"J Clin Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.07.029","article-title":"Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: real-world US ADVANTAGE study","volume":"154","author":"Bleecker E","year":"2024","unstructured":"Bleecker E, Blaiss M, Jacob-Nara J, et al.. Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: real-world US ADVANTAGE study. J Allergy Clin Immunol. 2024, 154:1500-10. 10.1016\/j.jaci.2024.07.029","journal-title":"J Allergy Clin Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/cea.14112","article-title":"Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis","volume":"52","author":"Charles D","year":"2022","unstructured":"Charles D, Shanley J, Temple SN, Rattu A, Khaleva E, Roberts G. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis. Clin Exp Allergy. 2022, 52:616-27. 10.1111\/cea.14112","journal-title":"Clin Exp Allergy"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/all.15986","article-title":"Tezepelumab in patients with allergic and eosinophilic asthma","volume":"79","author":"Caminati M","year":"2024","unstructured":"Caminati M, Buhl R, Corren J, et al.. Tezepelumab in patients with allergic and eosinophilic asthma. Allergy. 2024, 79:1134-45. 10.1111\/all.15986","journal-title":"Allergy"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-024-00653-6","article-title":"Safety of biological therapies for severe asthma: An analysis of suspected adverse reactions reported in the WHO pharmacovigilance databasea","volume":"38","author":"Cutroneo PM","year":"2024","unstructured":"Cutroneo PM, Arzenton E, Furci F, et al.. Safety of biological therapies for severe asthma: An analysis of suspected adverse reactions reported in the WHO pharmacovigilance databasea. BioDrugs. 2024, 38:425-48. 10.1007\/s40259-024-00653-6","journal-title":"BioDrugs"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-020-00442-0","article-title":"Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma","volume":"16","author":"Henriksen DP","year":"2020","unstructured":"Henriksen DP, Bodtger U, Sidenius K, et al.. Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma. Allergy Asthma Clin Immunol. 2020, 16:49. 10.1186\/s13223-020-00442-0","journal-title":"Allergy Asthma Clin Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/17534666251319175","article-title":"Adverse effects of biologics used to treat asthma","volume":"19","author":"Sitek A","year":"2025","unstructured":"Sitek A, Chiarella SE, Pongdee T. Adverse effects of biologics used to treat asthma. Ther Adv Respir Dis. 2025, 19:17534666251319175. 10.1177\/17534666251319175","journal-title":"Ther Adv Respir Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2025.04.012","article-title":"Patient outcomes and safety of combination biologic therapy with dupilumab: a systematic review","volume":"135","author":"Keow S","year":"2025","unstructured":"Keow S, Lu B, Xiong G, Yu E, Weng D, Abu-Hilal M. Patient outcomes and safety of combination biologic therapy with dupilumab: a systematic review. Ann Allergy Asthma Immunol. 2025, 135:23-30.e3. 10.1016\/j.anai.2025.04.012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1449194","article-title":"Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database","volume":"11","author":"Lin S","year":"2024","unstructured":"Lin S, Luo D, Gong Z, Zhan Q. Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database. Front Med (Lausanne). 2024, 11:1449194. 10.3389\/fmed.2024.1449194","journal-title":"Front Med (Lausanne)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2024.11.004","article-title":"Real-world mepolizumab treatment in eosinophilic granulomatosis with polyangiitis reduces disease burden in the United States","volume":"134","author":"Mathur SK","year":"2025","unstructured":"Mathur SK, Silver J, MacKnight SD, et al.. Real-world mepolizumab treatment in eosinophilic granulomatosis with polyangiitis reduces disease burden in the United States. Ann Allergy Asthma Immunol. 2025, 134:341-350.e2. 10.1016\/j.anai.2024.11.004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/life11080744","article-title":"Molecular targets for biological therapies of severe asthma: focus on benralizumab and tezepelumab","volume":"11","author":"Cheng SL","year":"2021","unstructured":"Cheng SL. Molecular targets for biological therapies of severe asthma: focus on benralizumab and tezepelumab. Life (Basel). 2021, 11:744. 10.3390\/life11080744","journal-title":"Life (Basel)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.11.021","article-title":"Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a\u00a0Bayesian network meta-analysis","volume":"151","author":"Nopsopon T","year":"2023","unstructured":"Nopsopon T, Lassiter G, Chen ML, Alexander GC, Keet C, Hong H, Akenroye A. Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a\u00a0Bayesian network meta-analysis. J Allergy Clin Immunol. 2023, 151:747-55. 10.1016\/j.jaci.2022.11.021","journal-title":"J Allergy Clin Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00306-2021","article-title":"Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma","volume":"7","author":"Pr\u00e6torius K","year":"2021","unstructured":"Pr\u00e6torius K, Henriksen DP, Schmid JM, et al.. Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma. ERJ Open Res. 2021, 7:10.1183\/23120541.00306-2021","journal-title":"ERJ Open Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1753440","article-title":"Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab","volume":"16","author":"Ridolo E","year":"2020","unstructured":"Ridolo E, Pucciarini F, Nizi MC, Makri E, Kihlgren P, Panella L, Incorvaia C. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab. Hum Vaccin Immunother. 2020, 16:2349-56. 10.1080\/21645515.2020.1753440","journal-title":"Hum Vaccin Immunother"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.06.036","article-title":"Dupilumab is effective in patients with moderate-to-severe uncontrolled GINA-defined type 2 asthma irrespective of an allergic asthma phenotype","volume":"10","author":"Rabe KF","year":"2022","unstructured":"Rabe KF, FitzGerald JM, Bateman ED, et al.. Dupilumab is effective in patients with moderate-to-severe uncontrolled GINA-defined type 2 asthma irrespective of an allergic asthma phenotype. J Allergy Clin Immunol Pract. 2022, 10:2916-2924.e4. 10.1016\/j.jaip.2022.06.036","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/388124-safety-and-efficacy-of-dupilumab-omalizumab-and-mepolizumab-in-moderate-to-severe-asthma-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T14:43:31Z","timestamp":1752849811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/388124-safety-and-efficacy-of-dupilumab-omalizumab-and-mepolizumab-in-moderate-to-severe-asthma-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.88236","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,18]]}}}